Platelet flow cytometry - A new dimension

LaboratoriumsMedizin

Volumn 26, Issue 11-12, 2002, Pages 594-599

  Scharwarz, Ulrike R ^a   Eigenthaler, M ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Drug monitoring; Flow cytometry; Platelets; Protein phosphorylation

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; MONOCLONAL ANTIBODY; TICLOPIDINE;

ANALYTIC METHOD; ARTICLE; BIOAVAILABILITY; DRUG MONITORING; FLOW CYTOMETRY; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE;

EID: 0036868223     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/LabMed.2002.066     Document Type: Article

References (34)

1. Eigenthaler M and Shattil SJ. Integrin Signaling and the Platelet Cytoskeleton. In: Nelson WJ (Ed.), Current Topics in Membranes, Vol 43: Membrane Protein-Cytoskeleton Interactions. Academic Press, San Diego, 1996;265-91.
2. Barlage S, Rothe G and Schmitz G. Platelet Analysis by Flow Cytometry. J Lab Med 2001;25:533-40.
3. Far DF, Peyron JF, Imbert V and Rossi B. Immunofluorescent quantification of tyrosine phosphorylation of cellular proteins in whole cells by flow cytometry. Cytometry 1994;15:327-34.
4. Vuillier F, Scott-Algara D, Cayota A, Siciliano J, Nugeyre MT and Dighiero G. Flow cytometric analysis of protein-tyrosine phosphorylation in peripheral T cell subsets. Application to healthy and HIV-seropositive subjects. J Immunol Methods 1995;185:43-56.
5. Hubert P, Grenot P, Autran B and Debre P. Analysis by flow cytometry of tyrosine-phosphorylated proteins in activated T-cell subsets on whole blood samples. Cytometry 1997;29:83-91.
6. Schwarz UR, Geiger J, Walter U and Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets - Definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999;82:1145-52.
7. Kieran MW and Zon LI. Stress- and mitogen-activated signal transduction in hematopoietic cells. Curr Opin Hematol 1996;3:27-34.
8. Dijkers PF, van Dijk TB, de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L and Coffer PJ. Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor. Oncogene 1999;18:3334-42.
9. Papkoff J, Chen RH, Blenis J and Forsman J. p42 mitogen-activated protein kinase and p90 ribosomal S6 kinase are selectively phosphorylated and activated during thrombin-induced platelet activation and aggregation. Mol Cell Biol 1994;14:463-72.
10. Kramer RM, Roberts EF, Strifler BA and Johnstone EM. Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem 1995;270:27 395-8.
11. Schwarz UR, Kobsar AL, Koksch M, Walter U and Eigenthaler M. Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and CD40 ligand/P-selectin expression by cyclic nucleotide-regulated pathways in human platelets. Biochem Pharmacol 2000;60:1399-407.
12. Schwarz UR, Walter U and Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001;62:1153-61.
13. Nolte C, Eigenthaler M, Schanzenbächer P and Walter U. Comparison of vasodilatory prostaglandins with respect to cAMP-mediated phosphorylation of a target substrate in intact human platelets. Biochem Pharmacol 1991;42:253-62.
14. Horstrup K, Jablonka B, Hönig-Liedl P, Just M, Kochsiek K and Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 1994;225:21-7.
15. Eigenthaler M, Ullrich H, Geiger J, Horstrup K, Hönig-Liedl P, Wiebecke D and Walter U. Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia. J Biol Chem 1993;268:13 526-31.
16. Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W, Fassler R, Ruth P, Krombach F and Hofmann F. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′-monophosphate kinase I. J Exp Med 1999;189:1255-64.
17. Schaefer A, Fraccarollo D, Hildemann S, Christ M, Eigenthaler M, Kobsar A, Ertl G and Bauersachs J. Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and ACE inhibition. European Society of Cardiology Congress Sept 2002, Berlin; in press.
18. Gabbeta J, Yang X, Kowalska MA, Sun L, Dhanasekaran N and Rao AK. Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses. Proc Natl Acad Sci USA 1997;94:8750-5.
19. Cattaneo M and Lecchi A. Patients with congenital abnormality of platelet aggregation induced by Ca(2+) ionophores may have a defect of the platelet P2Y(12) receptor for ADP. Br J Haematol 2001;115:485-7.
20. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR and Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest 1996;97:979-87.
21. Mitsui T, Yokoyama S, Shimizu Y, Katsuura M, Akiba K and Hayasaka K. Defective signal transduction through the thromboxane A2 receptor in a patient with a mild bleeding disorder: Deficiency of the inositol 1,4,5-triphosphate formation despite normal G-protein activation. Thromb Haemost 1997;77:991-5.
22. Smout J and Stansby G. Aspirin resistance. Br J Surg 2002;89:4-5.
23. Sokolova O, Schnurr A, Grossmann R, Kobsar A, Schwarz UR, Barragan P, Bonz A, Walter U and Eigenthaler M. Experiences with clopidogrel in patients with coronary heart disease: Are all platelets inhibited? Annals of Hematology 2002;81:A81.
24. Wehmeier A, Tschope D, Esser J, Menzel C, Nieuwenhuis HK and Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991;61:271-8.
25. Caranobe C, Sie P, Fernandez F, Pris J, Moatti S and Boneu B. Abnormal platelet serotonin uptake and binding sites in myeloproliferative disorders. Thromb Haemost 1984;51:349-53.
26. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64:1-12.
27. Ganguly P, Sutherland SB and Bradford HR. Defective binding of thrombin to platelets in myeloid leukaemia. Br J Haematol 1978;39:599-605.
28. Castaldi PA, Berndt MC, Booth W, Gregory C, Bull H and Greaves M. Evidence for a platelet membrane defect in the myeloproliferative syndromes. Thromb Res 1982;27:601-9.
29. Pareti FI, Gugliotta L, Mannucci L, Guarini A and Mannucci PM. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemost 1982;47:84-9.
30. Wautier JL, Souchon H, Dupuis D, Caen JP and Nurden AT. A platelet defect in a patient with eosinophilic leukaemia: Absent ristocetin-induced platelet aggregation associated with a reduced platelet sialic acid content. Scand J Haematol 1979;22:267-76.
31. Handa M, Watanabe K, Kawai Y, Kamata T, Koyama T, Nagai H and Ikeda Y. Platelet unresponsiveness to collagen: Involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemost 1995;73:521-8.
32. Le Blanc K, Berg A, Palmblad J and Samuelsson J. Stimulusspecific defect in platelet aggregation in polycythemia vera. Eur J Haematol 1994;53:145-9.
33. Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H, Wakui M, Handa M, Watanabe K, Okamoto S and Ikeda Y. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood 1996;88:4304-13.
34. Stenke L, Edenius C, Samuelsson J and Lindgren JA. Deficient lipoxin synthesis: A novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood 1991;78:2989-95.